BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

According to DealPulse’s M&A database, which harnesses both AI and attorneys to digest the granular deal points of publicly announced transactions, Regulus is advised by Latham & Watkins LLP, while ...

Nektar Therapeutics (NASDAQ:NKTR) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Nektar ...

Apart from four billion-dollar deals valued at $1bn or more driven by large pharma, the industry remains cautious given the ...

These large deals were Johnson & Johnson’s $14.6bn acquisition of Intra-Cellular Therapies, Novartis’ $3.1bn acquisition of Anthos Therapeutics, GSK’s $1.15bn buy of IDRx, and AstraZeneca ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be acquired by Novartis. 1 This will add the potential kidney disease treatment ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...